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Hemophilia 
 
by Charles Hall 
 
(Anatomy & Physiology 1552) 
 
 
 
Introduction 
emophilia is a rare genetic disorder that is estimated to affect 17,000 people in the United 
States. While it is now very well understood, documented, and managed, there is still 
misinformation surrounding the disease, such as how it is contracted, and whether it can be 
cured. In quick summary, hemophilia is an inherited genetic disorder that leads to improper clotting 
of the blood, and can easily lead to death by massive blood loss (Dowshen, 2011). There are three 
types of hemophilia, differentiated by the defective clotting factor they affect: Hemophilia A, which 
is the most common, causes a defect in gene F8, which is, and responsible for the correct 
manufacture of clotting factor VIII. Hemophilia B is only a quarter as common, and affects gene F9, 
which controls clotting factor IX. Hemophilia C is even more rare, affecting gene F11, which codes 
for clotting factor XI (Rogaev, 2009). It is important to note that hemophilia prevents fibrin 
formation for a clot to take hold. So a hemophiliac will not bleed as intensely, but will bleed for a 
longer period of time (Wilson, 2011). 
 
History 
 In 1803, Dr. John Conrad Otto was the first to scientifically document hemophilia. He 
noticed that the disease occurred primarily in males, and it seemed to run in a bloodline. Similar to 
hemophilia, he noted, but significantly different was Von Willebrand disease, differing from 
hemophilia in which the deficient factor is located. Hemophilia was especially prominent among 
members of the European royalty. European royalty tended towards inbreeding, so as to preserve 
their ―noble blood.‖ However, since hemophilia is a genetic disorder, this tended to pronounce the 
disease more heavily among members of this class. For this reason, hemophilia is also known as the 
―Royal disease‖ (Tortora, 2009). 
 
Signs and Symptoms 
 The symptoms of hemophilia are many, but are localized to the clotting mechanism of the 
blood. Hemophiliacs will bleed profusely, and rebleed easily. The times of the bleeds are excessive, 
and the amount of blood lost is potentially critical. In severe hemophiliacs, blood vessels around the 
joints can rupture spontaneously and bleed into the joints. Pain is not obvious at first, but as the joint 
becomes swollen with blood, it becomes hot to the touch and painful to bend. Because this is not 
quickly noticeable (or treatable), death occurs very commonly among hemophiliacs in this way. 
Parents will often become aware of the disease when frequent hematomas develop as the 
hemophiliac children begin to learn to walk. Nosebleeds will also occur at a higher than normal rate. 
Internal bleeding is a far more serious concern for hemophiliacs. Signs of internal bleeding include 
blood in the urine, blood in the stool, and large bruises covering or encircling an entire appendage. 
Bumps to the head are the most serious. Symptoms of this include migraines, neck stiffness, 
sleepiness, abrupt weakness, tunnel vision, and epilepsy (Haeomophilia Society, 2012). 
 
Causes 
 Now, the causes of hemophilia are well understood. Hemophilia can only be inherited. Both 
of the defective genes that hemophilia is associated with (F8 and F9) are both recessive-linked, 
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meaning they are transmitted to offspring by the X-chromosome only (Rogaev, 2009). Recall that, in 
the phylum Chordata (of which humans are a part), the offspring possess two gender genes, 
receiving one from each parent. Females have XX chromosomes, and males have XY chromosomes. 
In any case, the offspring will receive an X-chromosome from the female, and either an X or Y-
chromosome from the male. The gene the offspring receives from the male determines the 
offspring‘s sex. In the case of hemophilia, the X-chromosome carries a defective gene. The fact that 
hemophilia can only be transmitted by the X chromosome carries some implications with it: Since 
females have two X-chromosomes, females almost never present with the disease, instead being 
carriers of it. The remaining X-chromosome serves as a backup, stepping in to replace the defective 
clotting factor. Additionally, since males do not pass on an X-chromosome to male offspring, the 
disease cannot travel from father to son. Finally, females can carry the gene, but not show symptoms 
(carriers). Males who possess the defective X-chromosome will always present with symptoms; 
males cannot be carriers (Campbell, 2008). 
 Von Willebrand disease, which presents with similar symptoms to hemophilia, is approached 
and treated in a markedly different way. While hemophilia is caused by a deficient clotting factor, 
Von Willebrand is caused by a specific missing plasma protein called Von Willebrand factor (vWF). 
This protein is necessary for platelet adhesion. The absence of this protein can be a result of 4 
different genetic pathways, each of which defines a type of hereditary Von Willebrand disease. 
Therefore, there are 5 types of Von Willebrand disease, Type 1, Type 2A, Type 2B, Type 3, and 
Platelet type (Wilson, 2011). 
 
Diagnosis and Lab Tests 
 Hemophilia is usually diagnosed before birth, as the physician will recognize the risk 
involved. Four blood tests are used to diagnose hemophilia. These tests are PT, PTT, Bleeding Time, 
and Platelet Count. The purpose of these four is to definitively rule out other diseases (such as Von 
Willebrand) that mimic the symptoms of hemophilia. PT evaluates the extrinsic pathway of 
coagulation, and measures clotting factors I, II, V, VII, and X. In hemophilia, the time is unaffected. 
PTT evaluates the intrinsic pathway of coagulation, and measures clotting factors I, II, V, VIII, IX, 
X, XI, and XII. In all cases of hemophilia, PT will be unaffected, but PTT will be prolonged. 
Bleeding time (the test) is unaffected. This is because bleeding time measures the platelet activity, 
not the clotting factors. Finally, platelet count is a measure of the density of platelets in the blood, 
which gives an indication of how many platelets are circulating in the body. In people with 
hemophilia, the platelet count is normal. The purpose of bleeding time and platelet count, in the 
scope of diagnosing the disease, is to rule out other similar disorders. For example, Von Willebrand 
disease will show a normal PT and a prolonged PTT, but the bleeding time will also be prolonged. 
This is one of the ways hemophilia is differentiated from Von Willebrand disease (Wilson, 2011). 
 
Treatment and Management 
 Hemophilia can be very well controlled and treated. The first-choice for management is 
regular injections of the deficient clotting factor, VIII for hemophilia A and IX for hemophilia B. 
Some patients develop resistance to the clotting factors, so non-human clotting factors must then be 
given. If these fail, the patient can be given an excess of clotting factor VII, marketed as NovoSeven. 
While clotting factor VII is not one of the factors affected by hemophilia, an excess will help to form 
fibrin in the event of a bleed. These options can be administered in either a prophylactic manner, or 
an on-demand manner. Patients can elect to either inject regularly to maintain substantial levels of 
the deficient clotting factors, or they carry an emergency syringe in the event of an accident. 
However, this requires that they be aware of the incident. Internal bleeding is unnoticeable without 
any external cues (Tortora, 2007). This is evidenced by a 2007 study done by the New England 
Journal of Medicine, where children with hemophilia were studied based on their method of 
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treatment. Over time, children who chose the on-demand method of treatment suffered from joint 
degeneration, thought to be caused by unnoticed joint bleeding and synovial displacement (Manco, 
2007). However, costs of prophylactic treatment commonly reach $300,000 a year. In late 2011, 
scientists, using a gene virus, successfully inserted gene F9 into the genome of a hemophiliac. This 
type of gene therapy could become more cost effective than years of treatment (Wade, 2011). 
 
Prognosis 
 Prognosis for hemophiliacs is excellent. Even with on-demand treatment, major accidents can 
be prevented and worst-case scenarios avoided. Our understanding of the disease has also allowed us 
to treat major accidents in the most effective way possible (Wilson, 2011). 
 
Conclusion 
 As we have seen, hemophilia is very well understood and controlled. In the 1800‘s, 
hemophilia led to a massively decreased life span. Now, hemophiliacs, through proper management, 
can live to a normal lifespan without having to worry about bleeding excessively. Our understanding 
of the genetics behind hemophilia has also allowed us to approach each case in the most efficient and 
most effective way possible. Taking Anatomy and Physiology 1552 has helped me write this paper 
because we discussed how clotting occurs extensively. I found it much easier to understand how 
deficient clotting factors could influence the body‘s ability to form clots because of those 
discussions. I also found that our discussions on diabetes were helpful, as well. I was better able to 
recognize the benefits of consistent injections of the deficient clotting factor over intermittent, on-
demand injections. 
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